US FDA approves raltegravir for treatment of HIV-1 in neonates


eMediNexus    13 December 2017

The US Food and Drug Administration (FDA) has expanded the indication of the HIV drug raltegravir (Isentress, Merck) beyond adults and children aged 2 to 18 years to newborns weighing at least 2 kg making it the only approved integrase inhibitor for HIV-1 treatment in this population group, to be used in combination with other antiretroviral agents.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.